L&T Technology Services Unveils CoE to Offer Suite of Automotive Solutions on AWS
9.3.2023 10:30:00 EET | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global pure-play engineering services company, today announced a new Centre of Excellence (CoE) in Mysore (Karnataka, India) that leverages the power of the cloud with Amazon Web Services (AWS). The CoE will allow LTTS to transition its suite of cutting-edge technologies focused on the future of mobility and reduce time-to-market for end customers. By leveraging AWS infrastructure, LTTS will provide an opportunity to use AWS to support the automotive domain.
With its rich engineering domain expertise in Electric, Autonomous, and Connected Vehicles (EACV), LTTS has been helping OEMs to develop next-generation Vehicles and Aircraft that have tailored solutions focused on safety and security. The new CoE will leverage LTTS' cross-disciplinary skillsets covering embedded, mechanical, and digital facets of engineering.
LTTS has been actively working with global technology leaders like AWS to bring digital engineering solutions to end customers on the cloud. AnnotAI , Connected Cars , and SafeX are some of the LTTS solutions that will be deployed in AWS Marketplace to optimize R&D innovation on the cloud to create enterprise-leading technology solutions.
LTTS’ industry leading mobility solutions are helping OEMs to build innovative next-generation vehicles to meet and exceed the standards for transport safety, security, and emission regulations. LTTS’ AnnotAI, Connected Cars and SafeX solutions have already been deployed for leading global Automotive OEMs and Tier-1 customers, helping them reap significant faster time-to-market benefits. As part of the CoE, AWS software-defined vehicle and AWS IoT FleetWise will be used alongside LTTS’ digital offerings to collect and transfer the vehicle data to the cloud in near real time.
- AnnotAI : For the purpose of developing and testing a self-driving artificial intelligence (AI), a large amount of data is required, along with more engineering and data labeling services. LTTS’ intelligent data annotation platform AnnotAI provides smart labelling to media assets such as text, image, video, and LiDAR, thus empowering global vehicle manufacturers in their drive towards Level 5 autonomy (full driving automation or where the dynamic driving task is eliminated).
- Connected Car : LTTS’ Connected Car technologies offers automotive clients with state-of-the-art driver assistance systems, cloud services and connectivity modules which support in development of V2X platform definition, while implementing secured gateways and avoiding malicious attacks.
- SafeX : The automotive industry faces unique challenges when it comes to developing state-of-the-art software. SafeX DevOps and CI/CD automation allows automotive manufacturers to accelerate their releases while ensuring security and mitigating the risk of failed or recalled software releases.
LTTS’ suite of cutting-edge technologies has resulted in proven benefits for global customers.
A Spokesperson from BMW Group said, “The AnnotAI platform from LTTS, by enabling state-of-the-art image, video, and LiDAR data annotation capabilities on AWS, is driving a robust and integrated validation framework for BMW Group and helping the global leader in luxury vehicles engineer innovative and sustainable vehicles for the future.”
Amit Chadha, CEO and Managing Director, L&T Technology Services said, “Electric, Autonomous and Connected Vehicle (EACV) is the first of our six big bets that are helping global automotive players accelerate their technological development journey towards an autonomous and sustainable future built on the highest considerations of security and safety. By working with AWS, LTTS can help global automotive organizations realize the full potential of its high-performance and scalable technologies built on an agile AWS cloud infrastructure.”
Puneet Chandok, President of Commercial Business, AWS India & South Asia (Amazon Web Services India Pvt. Ltd.) said, “The digital transformation in the automotive industry is accelerating, in many cases thanks to innovative solutions coming from our AWS partners. LTTS’ digital engineering offerings will help our joint customers realize the benefits of moving to the cloud, such as reduced time to market, increased business value and accelerated pace of digital innovation. With the launch of the new Centre of Excellence in India, LTTS will enable customers and original equipment manufacturers (OEM) with a broader range of services and solutions to support their digital transformation journeys.”
Akshat Vaid, Partner at Everest Group said, “For some years now, innovation in mobility has been software and technology centric with themes such as hybrid and electric, autonomous driving, connected experiences, and shared mobility, continuing to be top ER&D spend segments. Cloud and edge computing are naturally at the front and centre in this new era of automotive engineering. Alliances between cloud leaders and engineering service providers will go a long way in helping OEMs in driving best engineering outcomes and in the process creating new possibilities for their end-consumers.”
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 21,600 employees spread across 22 global design centers, 28 global sales offices and 91 innovation labs as of December 31, 2022. For more information, please visit www.ltts.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005905/en/
Contact information
Aniruddha Basu
L&T Technology Services Limited
E: Aniruddha.basu@ltts.com
T: +91-80-67675707
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom